Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 16/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | FECH | P22830 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163651 | 0.88 | CHEK1 (0.47) | CHEK1CHEK2AURKAMARK3PRKCD | |
| SCHEMBL2034352 | 0.87 | KDM4E (0.51) | CHEK1CHEK2AURKAMARK3PRKCD | |
| SCHEMBL5380675 | 0.85 | CHEK1 (0.54) | CHEK1CHEK2AURKAMARK3PRKCD | |
| SCHEMBL2035469 | 0.83 | KDM4E (0.51) | CHEK1CHEK2AURKAMARK3PRKCD | |
| SCHEMBL4299163 | 0.81 | CHEK1 (0.54) | CHEK1CHEK2AURKAMARK3PRKCD | |
| SCHEMBL5163913 | 0.79 | CHEK1 (0.51) | CHEK1CHEK2AKT1 | |
| SCHEMBL5163485 | 0.79 | CHEK1 (0.51) | CHEK1CHEK2AURKAMARK3PRKCD | |
| SCHEMBL14517909 | 0.78 | KMT2A (0.51) | CHEK1HRH3 | |
| SCHEMBL5162739 | 0.78 | CHEK1 (0.50) | CHEK1CHEK2AURKAMARK3PRKCD | |
| SCHEMBL5164420 | 0.77 | CHEK1 (0.44) | CHEK1FECHKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | ICOS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1667684-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005027907-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | CHEK1, CHEK2, CDC25C | CHEK1 1/4885CHEK2 2/4885AURKA 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.